Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atropine/chlorphenamine/pseudoephedrine - MAGNA Pharmaceuticals

Next Previous
Drug Profile

Atropine/chlorphenamine/pseudoephedrine - MAGNA Pharmaceuticals

Alternative Names: Atr/CM/PSE - Magna Pharmaceuticals; Atropine/chlorpheniramine/pseudoephedrine - MAGNA Pharmaceuticals; Atropine/pseudoephedrine/chlorphenamine - MAGNA Pharmaceuticals; Chlorphenamine/atropine/pseudoephedrine - MAGNA Pharmaceuticals; Chlorphenamine/pseudoephedrine/atropine - MAGNA Pharmaceuticals; Chlorpheniramine/pseudoephedrine/atropine - MAGNA Pharmaceuticals; Pseudoephedrine/atropine/chlorphenamine - MAGNA Pharmaceuticals; Pseudoephedrine/chlorphenamine/atropine - MAGNA Pharmaceuticals; StahistRx

Latest Information Update: 21 Jun 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MAGNA Pharmaceuticals
  • Class Alkaloids; Antiallergics; Antihistamines; Decongestants; Propanolamines; Pyridines; Small molecules; Tropanes
  • Mechanism of Action Alpha adrenergic receptor agonists; Cholinergic receptor antagonists; Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Seasonal allergic rhinitis

Most Recent Events

  • 21 Jun 2016 No recent reports on development identified - Phase-II for Seasonal allergic rhinitis (In adolescents and adults) in USA (PO)
  • 29 May 2014 MAGNA Pharmaceuticals completes enrolment in its phase II trial for Seasonal allergic rhinitis (In adolescents and adults) in USA (NCT02082054)
  • 31 Mar 2014 Phase-II clinical trials in Seasonal allergic rhinitis (In adolescents and adults) in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top